Tuesday, May 31, 2016

FDA grants Profound Medical IDE approval for TULSA-PRO

FDA grants Profound Medical IDE approval for TULSA-PRO

May 19, 2016 by · Leave a Comment 

Tweet Profound Medical (TSX-V:PRN) has received investigational device exemption (IDE) approval from the FDA for a multicenter pivotal clinical trial to evaluate the efficacy of the TULSA-PRO System in patients with localized prostate cancer. TULSA-PRO, which has received CE Mark in Europe, combines real-time MRI with transurethral robotically-driven ultrasound and closed-loop thermal feedback control, providing […]

Profound Medical, Royal Phillips in TULSA-PRO sales pact

Profound Medical, Royal Phillips in TULSA-PRO sales pact

May 11, 2016 by · Leave a Comment 

http://www.youtube.com/watch?v=Wyy5jLOi8ac’]

Tweet Profound Medical (TSX-V:PRN) and Royal Philips have signed a sales and marketing agreement that will advance the commercial launch of Profound’s TULSA-PRO, a minimally invasive system to ablate targeted prostate tissue. Under the accord, the two companies will collaborate in the commercialization of TULSA-PRO in Europe followed by Canada, the U.S. and other markets, […]

Profound Medical readies pivotal clinical trial of TULSA-PRO

Profound Medical readies pivotal clinical trial of TULSA-PRO

May 3, 2016 by · Leave a Comment 

http://www.youtube.com/watch?v=Wyy5jLOi8ac’]

Tweet After receiving CE Mark approval last month of its minimally invasive transurethral ultrasound technology for the ablation of benign and malignant prostate tissue, known as TULSA-PRO, Profound Medical (TSX-V:PRN) plans to enroll 14 sites in the U.S., Canada and Europe in a pivotal trial for U.S. regulatory approval. “We have discussions ongoing with the […]

Profound Medical sells first TULSA-PRO device

Profound Medical sells first TULSA-PRO device

April 28, 2016 by · Leave a Comment 

Tweet Profound Medical (TSX-V:PRN) has made the first sale of its TULSA-PRO device to ResoFus Alomar in Barcelona, Spain. Profound’s novel technology combines real-time magnetic resonance imaging with transurethral robotically driven ultrasound and closed-loop thermal feedback control, providing a highly precise treatment tailored to patient-specific anatomy and pathology. TULSA-PRO has demonstrated accurate and precise ablation […]

Transition Therapeutics begins Phase 2 SARM study

Transition Therapeutics begins Phase 2 SARM study

April 26, 2016 by · Leave a Comment 

Tweet Transition Therapeutics (NASDAQ:TTHI, TSX:TTH) has dosed the first patient in a Phase 2 study of selective androgen receptor modulator (SARM) drug candidate, TT701. The Phase 2 study will evaluate the efficacy and safety of TT701 in improving the symptoms of androgen deficiency, including sexual symptoms, fatigue/low vitality, and physical dysfunction in men who have […]

GMP starts Profound Medical at speculative buy

GMP starts Profound Medical at speculative buy

April 12, 2016 by · Leave a Comment 

Tweet GMP Securities has initiated coverage of Profound Medical (TSX-V:PRN) with a “speculative buy” rating and price target of $2. The stock closed at $1.50 on Monday. The company is focused on developing and commercializing an innovative therapy for the ablation of prostate cancer tissue, using real-time MRI to greatly improve accuracy, while reducing side […]

Soricimed to present four posters at AACR

Soricimed to present four posters at AACR

April 12, 2016 by · Leave a Comment 

Tweet Closely-held Soricimed Biopharma and collaborators plan to present four posters at the American Association of Cancer Research (AACR) annual meeting in New Orleans on April 16-20. The presentations are based on preclinical and clinical research conducted on the company’s lead anti-cancer drug candidate, SOR-C13, a first-in-class inhibitor of the TRPV6 calcium channel. In February, […]

Profound Medical receives CE Mark to sell Tulsa-Pro

Profound Medical receives CE Mark to sell Tulsa-Pro

April 11, 2016 by · Leave a Comment 

Tweet Profound Medical (TSX-V:PRN) has received CE Mark approval for the commercial sale of Tulsa-Pro. Profound’s novel technology combines real-time magnetic resonance imaging with transurethral robotically-driven ultrasound and closed-loop thermal feedback control to provide a highly precise treatment tailored to patient-specific anatomy and pathology. TULSA-PRO has demonstrated accurate and precise ablation of prostate tissue, both […]

Transition Therapeutics sets Phase 2 SARM trial

Transition Therapeutics sets Phase 2 SARM trial

October 30, 2015 by · Leave a Comment 

Tweet Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) has entered an agreement for an investigator-led clinical study of drug candidate, TT701, with Brigham and Women’s Hospital (BWH). Transition will support the Phase 2 study to evaluate selective androgen receptor modulator (SARM) drug candidate TT701 as a therapy to improve the symptoms of androgen deficiency in men with prostate cancer who […]

Can-Fite preparing protocol for advanced psoriasis trial

Can-Fite preparing protocol for advanced psoriasis trial

September 8, 2015 by · Leave a Comment 

Tweet Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) is preparing the protocol for its next advanced psoriasis trial with its CF101 oral drug candidate, even though an earlier Phase 2/3 study did not meet its primary endpoint. The earlier trial was designed to show a statistically significant improvement in the Psoriasis Area Severity Index (PASI) 75 score, […]

Next Page »

Email Newsletters with Constant Contact
Google+